Cover Image
Market Research Report
Product code
974122

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Published: | BCC Research | 88 Pages | Delivery time: 1-2 business days

Price

Back to Top
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Published: November 27, 2020
BCC Research
Content info: 88 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Highlights:

The global market for Alzheimer’s disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.

The North American market for Alzheimer’s disease treatment should grow from $2.5 billion in 2020 to $3.3 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

The Asia-Pacific market for Alzheimer’s disease treatment should grow from $1.3 billion in 2020 to $1.7 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

Report Scope:

The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (AB) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat, i.e., mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).

Report Includes:

  • 27 tables
  • An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
  • Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates
  • Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
  • Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
  • Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World
  • Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi
Table of Contents
Product Code: PHM062D

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Alzheimer's Disease: Definition and Market Structure
  • Alzheimer's Disease Pathophysiology
  • AD and Amyloid Cascade
  • AD and Tauopathy
  • AD and Neurotransmitter Systems
  • Alzheimer's Disease Etiology
  • Genetic Factors
  • Non-Genetic Factors
  • Alzheimer's Disease Epidemiology
  • Age of Onset
  • Incidence, Prevalence and Mortality
  • Stages and Severity of AD
  • Comorbidities
  • Diagnosis and Treatment of Alzheimer's
  • Diagnosis of Alzheimer's
  • Companion Imaging Diagnostics for AS
  • CIDX Technologies for Amyloid Visualization
  • CIDX Technologies for TAU-NFT Visualization
  • Comparative Analysis of Tau Tracers in Development
  • CIDX Technologies: AB vs. Tau Imaging Technologies
  • Concluding Remarks
  • Pharmaceutical Treatment of AD

Chapter 4 Regulatory Structure

  • U.S.
  • Accelerated Approvals
  • Fast Track Designation
  • Breakthrough Therapy Designation
  • Priority Review
  • Controlled Substances Act
  • Special Protocol Assessments
  • New Surveillance and Safety Requirements
  • Canada
  • Mexico
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Reimbursement Landscape

Chapter 5 Market Dynamics

  • Market Drivers
  • Use of Biomarkers in Diagnosis and Drug Development
  • Large Number of Drugs in the Pipeline
  • Market Restraints
  • Patent Expirations of Branded Drugs and Emergence of Generics
  • High Failure Rate in Drug Development
  • High Cost of Drug Development

Chapter 6 Global Markets for Alzheimer's Disease Therapeutics

  • Market Overview
  • Global Market for Alzheimer's Drugs by Mechanism of Action
  • Acetylcholinesterase Inhibitors (AChEIs)
  • NMDA Drugs
  • Global Market for Branded/Generic AD Therapeutics by Type
  • Global Market for AD Therapeutics by Stage of AD

Chapter 7 Market Breakdown by Region

  • Global Market for Alzheimer's Drugs by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Industry Structure
  • Impact of Generic AD Therapeutics

Chapter 8 Pipeline Analysis

  • Overview of the Drug Development Process
  • Phase III
  • Phase II
  • Phase I
  • Trial Sponsors

Chapter 9 Company Profiles

  • ABBVIE
  • ACADIA PHARMACEUTICALS INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO., LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO.
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UCB SA

Chapter 10 Appendix: Acronyms

List of Tables

  • Summary Table : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 1 : Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Table 2 : Pharmacological Treatment of BPSD of Alzheimer's
  • Table 3 : Computerized Screening Tests Used in Detecting Cognitive Impairment
  • Table 4 : Brain Imaging Technologies and Application in the Alzheimer's Context
  • Table 5 : Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 6 : Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
  • Table 7 : Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
  • Table 8 : Global Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 9 : Global Market for AD Therapeutics, by Disease Stage, Through 2025
  • Table 10 : Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
  • Table 11 : Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
  • Table 12 : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 13 : North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 14 : North American Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 15 : North American Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 16 : European Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 17 : European Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 18 : European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 19 : Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 20 : Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 21 : Global Ranking of Leading Players in Alzheimer's Disease Drugs
  • Table 22 : Agents in Phase III of Alzheimer's Disease Drug Development
  • Table 23 : Agents in Phase II of Alzheimer's Disease Drug Development
  • Table 24 : Agents in Phase I of Alzheimer's Disease Drug Development
  • Table 25 : Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
  • Table 26 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 1 : Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Figure 2 : Pharmaceutical Regulatory Pathways in the U.S. and Europe
  • Figure 3 : Global Market for Alzheimer's AChEIs Drugs, 2019-2025
  • Figure 4 : Global Market for Alzheimer's NMDA Drugs, 2019-2025
  • Figure 5 : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 6 : North American Market for Alzheimer's Drugs, 2019-2025
  • Figure 7 : European Market for Alzheimer's Drugs, 2019-2025
  • Figure 8 : Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
  • Figure 9 : South American Market for Alzheimer's Drugs, 2019-2025
  • Figure 10 : Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025